Bristol Myers Squibb (CELG-RI) Other Non Operating Income (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Other Non Operating Income for 18 consecutive years, with $61.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Non Operating Income rose 112.35% year-over-year to $61.0 million; the TTM figure through Jun 2026 stood at $188.0 million (up 113.7% YoY), while the FY2025 annual figure was -$997.0 million, down 3.0% from the prior year.
• Other Non Operating Income climbed to $61.0 million in Q2 2026 per CELG-RI's latest filing, from -$32.0 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $413.0 million in Q1 2023 and bottomed at -$649.0 million in Q1 2022.
• Historically, Other Non Operating Income has averaged -$53.1 million across 5 years, with a median of $9.5 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non Operating Income plunged 14300.0% — and 2023, when it surged 163.64%.
• Bristol Myers Squibb's Other Non Operating Income stood at $217.0 million in 2022, then jumped by 70.97% to $371.0 million in 2023, then slumped by 182.21% to -$305.0 million in 2024, then jumped by 116.72% to $51.0 million in 2025, then climbed by 19.61% to $61.0 million in 2026.
• Business Quant data shows CELG-RI's Other Non Operating Income at $61.0 million in Q2 2026, -$32.0 million in Q1 2026, and $51.0 million in Q4 2025.